.INVESTIGATION FEATURE.16 Oct 2024.
In the NIAGARA trial, the enhancement of perioperative durvalumab to common treatment for muscle-invasive bladder cancer cells strengthened event-free and overall survival, marking a brand new therapy choice for this ailment.